Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

It certainly seems like the TAM for Brinsupri has a lot of room to expand with a very well designed strategy to identify ...

For patients with non-large vessel occlusion, acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Amyotrophic Lateral Sclerosis Therapeutics Market size & share revenue was ...

A new survey finds many American workers feel their pay is not keeping up with the rising cost of living. More than half of workers have less than three months of living expenses saved in case of a ...

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is ...

This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...

Natalizumab originator (Tysabri, Biogen) and natalizumab biosimilar (Tyruko, Sandoz) are indicated as a 'single disease-modifying therapy in adults with highly active relapsing–remitting multiple ...

Getting the right vitamins and minerals through diet or supplementation can help support bone strength, heart health, energy levels, and healthy aging.

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical. Comprehensive ...

Artificial intelligence won’t destroy the software business. But the persistent belief that it will can still do a lot of damage. And that has already been done. Software stocks have been on a ...